{"id":58829,"date":"2026-03-05T13:31:43","date_gmt":"2026-03-05T05:31:43","guid":{"rendered":"https:\/\/flcube.com\/?p=58829"},"modified":"2026-03-05T13:31:43","modified_gmt":"2026-03-05T05:31:43","slug":"cmss-cms-d008-wins-nmpa-approval-inhbe-sirna-targets-fat-selective-weight-loss","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58829","title":{"rendered":"CMS’s CMS-D008 Wins NMPA Approval \u2013 INHBE siRNA Targets Fat\u2011Selective Weight Loss"},"content":{"rendered":"\n

China Medical System Holdings Limited (CMS, HKG:\u202f0867<\/a>)<\/strong> announced clinical study approval<\/strong> from China’s National Medical Products Administration (NMPA)<\/strong> for CMS-D008 injection<\/strong>, a novel siRNA therapy<\/strong> targeting INHBE (inhibin subunit beta E)<\/strong> for overweight or obese individuals<\/strong>. The subcutaneously administered RNAi therapeutic<\/strong> represents a next\u2011generation metabolic approach<\/strong>\u2014reducing fat mass while preserving lean muscle<\/strong>\u2014potentially differentiating from GLP\u20111\u2011based therapies<\/strong> that cause significant muscle loss<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>China Medical System Holdings Limited (CMS, HKG:\u202f0867)<\/td><\/tr>
Product<\/strong><\/td>CMS-D008 injection<\/td><\/tr>
Drug Class<\/strong><\/td>Novel siRNA therapy<\/td><\/tr>
Administration<\/strong><\/td>Subcutaneous injection<\/td><\/tr>
Regulatory Action<\/strong><\/td>NMPA clinical study approval<\/td><\/tr>
Indication<\/strong><\/td>Overweight\/obesity<\/td><\/tr>
Target<\/strong><\/td>INHBE gene<\/strong> (hepatic expression reduction)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mechanism of Action \u2013 INHBE\/Activin E Pathway<\/h2>\n\n\n\n
Component<\/th>Function<\/th>Therapeutic Effect<\/th><\/tr><\/thead>
INHBE Gene<\/strong><\/td>Encodes Activin E protein<\/td>Silencing reduces Activin E production<\/td><\/tr>
Activin E-ALK7 Signaling<\/strong><\/td>Promotes fat accumulation<\/td>Pathway blockade \u2192 reduced fat storage<\/strong><\/td><\/tr>
siRNA Approach<\/strong><\/td>Hepatic INHBE mRNA degradation<\/td>Sustained, specific gene silencing<\/strong><\/td><\/tr>
Clinical Outcome<\/strong><\/td>Fat\u2011selective weight loss<\/td>Preserves lean mass<\/strong>; “high\u2011quality” weight reduction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Preclinical Evidence<\/h2>\n\n\n\n
Study Model<\/th>CMS-D008 Result<\/th><\/tr><\/thead>
INHBE Expression<\/strong><\/td>Efficient and sustained suppression<\/strong><\/td><\/tr>
Diet\u2011Induced Obesity<\/strong><\/td>Enhanced weight loss<\/strong> via fat mass reduction<\/td><\/tr>
Body Composition<\/strong><\/td>Retained lean mass<\/strong> with fat\u2011specific loss<\/td><\/tr>
Safety Profile<\/strong><\/td>Good tolerability demonstrated<\/td><\/tr>
Differentiation<\/strong><\/td>Potentially superior to GLP\u20111s<\/strong> in muscle preservation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n